Dimebon

Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009

...ement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's an...es. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several...hase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer...

New Treatments for Alzheimer's on the Horizon

... Studies show dimebon could improve cognition, vaccine might fight 'tang...ogression of Alzheimer's disease. A drug called dimebon seems to improve cognitive function in both mice a...think about amyloid, or both." It could be that dimebon neutralizes then expels the excess amyloid from th...

Medivation to Present at 8th Annual Needham Life Sciences Conference

...divation and its clinical development programs for dimebon for Alzheimer's and Huntington's diseases and MDV3...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several...

Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...nts with mild-to-moderate Alzheimer's disease. The dimebon program also includes additional trials planned to...

Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...s. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update

...nt progress with both of our product candidates -- dimebon in patients with Alzheimer's and Huntington's dise...an to support a broad and differentiated label for dimebon in Alzheimer's disease, we are pleased to have initiated the Phase 3 CONCERT trial of dimebon in combination with donepezil (Aricept(R)), and in...

For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions

...se-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading age...

Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Dimebon in Medical Technology

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease

--New 12-month study broadens Phase 3 clinical program to further evaluate the benefits of Dimebon in Alzheimer's Disease-- NEW YORK and SAN FRANCISCO, April 15 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE ) and Medivation, Inc. (Nasdaq: MDVN ) today announced the initiation of a 12-mont...

Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease

- Dimebon Improved the Clinical Course of Alzheimer's Disease; Patients Experienced Statistically Significant Improvements in Memory and Thinking, Activities of Daily Living, Behavior and Overall Function - SAN FRANCISCO, July 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ...

Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease

- Dimebon Significantly Improves Cognition and is Well Tolerated in Huntington's Disease Patients - - Findings Warrant Further Development in Huntington's Disease - - Conference Call Scheduled for Today at 5:00 p.m. EDT - SAN FRANCISCO, July 7 /PRNewswire-FirstCa...

Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimer's Disease Study

SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Dimebon(TM),...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at Six Months - SAN FRANCISCO and WASHINGTON, June 11, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the benefits of Dimebon over placebo in its double-blind, placebo-controlled Phase 2 study in mild-to- moderate Alzhe...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... Level of a Toxic Protein Recent evidence suggests that the drug dimebon may improve cognitive function in people with mild to moderate Alzheimer's,...n a surprising result from ICAD 2009, researchers found that treatment with dimebon caused an increase in a brain protein, known as beta amyloid, in animal mod...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several...hase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer...

Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease

...he safety and efficacy of the investigational drug dimebon as a treatment for mild-to-moderate Alzheimer's di...ool of Medicine. "Results from a previous study of dimebon in Alzheimer's disease were encouraging, and we lo...to learn more about this trial." About Dimebon dimebon is an investigational therapy in clinical developm...

Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD

...Month Data from an Extension of a Pivotal Trial of dimebon in Alzheimer's In a study recently reported, dimebon (Medivation) improved cognition and memory, activi...ticipants (54 Dimebon, 50 placebo). All were given dimebon for the OLE, not placebo, at a dose of 20 mg three...

Dimebon in Biological Technology

Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's d...

Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon

SAN FRANCISCO, Sept. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Wednesday, September 3, to discuss partnering plans for Dimebon. Teleconference/Webcast Details To participate in the li...

Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Medivation Announces Upcoming Scientific Presentations at Medical Conferences

...7. Prostate Cancer: Advanced dimebon 61st American Academy of Neurology (AAN) Annu... Two poster presentations featuring dimebon that will take place on: Wednesday, Ap...ostate cancer, including bicalutamide. About dimebon ...

Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update

... Phase 3 testing in all of our programs in 2009 -- dimebon in both Alzheimer's and Huntington's diseases and ...ng a comprehensive Phase 3 development program for dimebon in Alzheimer's disease and are already well on our...ate, and the soon-to-be-initiated CONCERT study of dimebon in combination with Aricept. In addition, with Pf...

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...s. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon in patients with mild-to-moderate Huntington's dis...

Medivation Presents New Data on Dimebon's Novel Mechanism of Action

...drial mechanism of action. In preclinical studies, dimebon was shown to impact two key aspects of brain cell ...posed to different toxins, including beta amyloid, dimebon was shown to stabilize mitochondrial function, a v...ment for Medivation. "These findings suggest that dimebon may have benefits on slowing the progression of Al...

Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference

...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...es. With Pfizer, the Company is conducting a broad dimebon clinical development program, including a pivotal ...eimer's disease, as well as further development of dimebon for patients with mild-to-moderate Huntington's di...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update

... an extensive program to support a broad label for dimebon in Alzheimer's disease beyond our original plan to...izer Inc. to jointly develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...tolerability study of combination therapy with dimebon and donepezil (Aricept(R)) in patients with Al...

Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008

...cludes a pivotal and confirmatory Phase 3 trial of dimebon in Alzheimer's disease and a Phase 1-2 clinical tr...d that it plans to continue further development of dimebon in patients with mild-to-moderate Huntington's dis...ement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer's and Huntington's ...